Introduction: Vaccination plays a fundamental role in mastering the COVID-19 pandemic and protecting vulnerable groups. Persons with autoimmune inflammatory rheumatic diseases (AIIRD), on immunosuppressive therapies, are prioritized for vaccination. However, data concerning immunogenicity and safety of the BBIBP-CorV vaccine in immunosuppressed patients are not found. This study presents data on the efficacy and safety of the BBIBP-CorV vaccine in immunosuppressed patients compared to healthy controls. Methods: Study population consisted of 100 healthy controls and 100 patients with AIIRD. Vaccination was performed according to national guidelines with the BBIBP-CorV vaccine. SARS-CoV2 neutralizing antibody titers were quantified by ELISA before initial vaccination and 1–3 months after secondary vaccination. Adverse events were assessed before study initiation and 7 days after the second dose. Disease activity was studied before entering the study and 3-8 weeks after the second dose. Results: Vaccination-induced positive immunogenic response rates and SARS-CoV2 neutralizing antibody titers were significantly lower in the AIIRD patients than healthy subjects (P<0.05). There are significant differences in neutralizing antibody titers among patients suffering from RA, SLE, SSc, and AS (P<0.01-0.05). The rates of seropositive vaccine responses were similarly distributed across all diseases. Healthy and AIIRD individuals had a similar profile in adverse events. No significant difference was observed in SARSCoV2 antibody titers between subjects suffering from side effects and those who did not have. SARS-CoV2 neutralizing antibody levels were significantly higher in SARS-CoV2-infected persons than noninfected subjects (P<0.01-0.05). Seropositive subjects had a significant increase in the percentage of vaccine-related adverse events compared to seronegative persons (P<0.05). Despite a minor change in the disease activity of patients with RA and SLE, disease activity indices were overall stable in the AIIRD patients. Conclusion: The BBIBP-CorV vaccine is effective in the development of neutralizing antibody in immunosuppressed patients without considerable reactogenicity or induction of disease flares.

Cancer as a terrible disease ranks among the most important healthcare issues confronting humanity, necessitating a proactive approach to treatment. Numerous signaling cascades are involved in the complex process of carcinogenesis. Despite its success, chemotherapy has had some undesirable side effects. Plants offer a rich source of novel substances and represent an exciting new option for cancer research. Plants and plant-derived products are revolutionizing themselves because they are less poisonous, quicker, cheaper, safer, and simpler than standard treatment procedures. Natural products are viewed as viable candidates for the creation of anticancer medicines because of their pleiotropic effects on target events in a variety of ways. The actions of plant-derived products are selective; they damage cancer cells and have no significant effect on healthy cells. Several researches are being conducted on the production of potential candidates from these plant-derived products that can stop or inhibit cancer cell proliferation without causing adverse effects. Numerous plant-derived products and the analogs from which they were derived have been identified as potential anticancer therapeutic possibilities. In this review, we summarize research on botanical products with significant and active anticancer activity and their anticancer constituents, with a focus on breast cancer. This review sought to highlight the most recent advances and key successes in plant-derived products and cancer therapies focusing on nuclear and cellular structures. Furthermore, cancer drugs and their problems are discussed.

Autosomal-dominant hyper-IgE (AD-HIES) is mainly characterized by eczematous dermatitis, staphylococcal skin abscesses, connective tissue defects, and elevated serum IgE. This disorder is largely associated with heterozygous dominant-negative mutations in STAT3 gene. Herein, we reported a patient with AD-HIES suffering from dental abnormality and allergic reactions.

Thrombocytosis, an uncommon side effect of all-trans retinoic acid (ATRA) treatment, occurs in some patients with acute promyelocytic leukemia. Our case showed thrombocytosis on day 26 to day 32 of ATRA and arsenic trioxide therapies and then started to decrease gradually without changing ATRA dosage. Thrombocytosis may associate with cytokine.

Ataxia-telangiectasia (A-T) is a multi-system disorder, resulted from the mutation in the ATM gene. Its mortality is largely related to some other disorders. Therefore, the management of its complications significantly improves patient quality of life. We studied a pediatric patient with A-T who one of his relatives had A-T.